Myositis
Methodology & AI Transparency ⓘ
Myositis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Myositis means inflammation of the muscles that you use to move your body.
- 2 Real-world patient consensus: Diagnostic registry M60.9: Myositis is managed within Skin & Dermatology.
- 3 Typical cash cost range: Clinicians assessing Myositis focus on cutaneous immune skewing in Myositis (M60.9: (Th2/IL-4/IL-13 in atopic) and targeted history.
- 4 Top reported side effects / signs: Longitudinal Myositis monitoring tracks Affected Body Surface in Myositis (M60.9: Area (BSA /) toward Clear or Almost Clear (IGA 0–1) (M60.9).
Ask our AI Specialists anything about Myositis
What Is Myositis?
Myositis means inflammation of the muscles that you use to move your body. An injury, infection, or autoimmune disease can cause it. Two specific kinds are polymyositis and dermatomyositis. Polymyositis causes muscle weakness, usually in the muscles closest to the trunk of your body. Dermatomyositis causes muscle weakness, plus a skin rash. Other symptoms of myositis may include: Fatigue after walking or standing Tripping or falling Trouble swallowing or breathing Doctors may use a physical exam, lab tests, imaging tests and a muscle biopsy to diagnose myositis. There is no cure for these diseases, but you can treat the symptoms.
Pathophysiology, Underlying Causes & Clinical Presentation
In Myositis (M60.9), physiological disruption stems from cutaneous immune skewing in Myositis (M60.9: (Th2/IL-4/IL-13 in atopic), Cross-referenced with NIH MeSH (Myositis), informing Dermatology: Acne, Eczema, Psoriasis & Rosacea protocols that track Fasting Lipids & in Myositis (M60.9: ALT (if systemic) (Within baseline reference limits (M60.9)).
Common Symptoms & Clinical Signs
- • Fatigue after walking or standing
- • Tripping or falling
- • Presentation of Myositis (M60.9): compromised epidermal barrier in Myositis (M60.9: with dryness, fissuring,)
- • Secondary Myositis clinical sign: post-inflammatory hyperpigmentation, facial in Myositis (M60.9: flushing, or pitted)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Myositis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M60.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Affected Body Surface in Myositis (M60.9: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (M60.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Myositis (M60.9: ALT (if systemic) | Within baseline reference limits (M60.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Myositis (M60.9: & hs-CRP) | 25(OH)D 40–65 ng/mL (M60.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Myositis
Treatment selection for Myositis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Myositis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Stubborn Plaque Psoriasis? A Targeted New Antibody Cleared Skin in a 461-Patient Trial Vunakizumab has better efficacy than placebo with satisfactory safety profiles in patients with moderate-to-severe plaque psoriasis skin flare-ups skin flare-ups who have a history of systemic therapies. International immunopharmacology • 2026-03-01 • Phase III Randomized Trial | N = 307 | 93/100 | PMID 41547249 ↗ |
| Can This Approach Help? Inside the Latest Research on Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results Secukinumab demonstrated strong and clinically meaningful efficacy for up to 2·5 years in nail psoriasis, with significant sustained QoL improvements and a favourable safety profile. The British journal of dermatology • 2021-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 32479641 ↗ |
| New Insights on Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With: What a 218-Participant Study Found Of the 491 patients who entered phase A (mean age, 60.7 [SD, 10.2] years; 246 women [50.1%]; 170 with coronary heart disease [34.6%]; entry mean LDL-C level, 212.3 [SD, 67.9] mg/dL), muscle symptoms occurred in 209 of 491... JAMA • 2016-04-19 • Randomized Controlled Trial | N = 218 | 88/100 | PMID 27039291 ↗ |
| Can This Approach Help? Inside the Latest Research on Etretin therapy for severe psoriasis. Evaluation of initial clinical Etretin showed equivalent efficacy to that previously reported with etretinate in severe recalcitrant plaque psoriasis skin flare-ups skin flare-ups vulgaris. Archives of dermatology • 1987-01-15 • Randomized Controlled Trial | N = 21 | 88/100 | PMID 2948451 ↗ |
| Can This Approach Help? Inside the Latest Research on Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two Patients who crossed over to deucravacitinib at week 16 achieved similar improvements at week 52 as patients treated continuously with deucravacitinib from day 1. Clinical and experimental dermatology • 2025-09-25 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40411449 ↗ |
Myositis Patient Community & “People Like Me” Threads
Filter Myositis community threads and patient logs by age, biological sex, dosage, and treatment duration.